DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Topp MS, Gökbuget N, Zugmaier G. et al.
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
J Clin Oncol 2014;
32 (36) 4134-4140
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.